Seven Australian startups awarded $15.6M in equity-free grants for dementia and cognitive-decline projects

Seven Australian health startups received a combined $15.6 million in equity-free grants under the CUREator+ Dementia & Cognitive Decline program, funded by the government's Medical Research Future Fund. The awards are aimed at advancing early-stage therapies, diagnostics, medical devices, assistive technology and digital health solutions with commercial potential.

The recipients and their stated projects are:

• Kinoxis Therapeutics (Melbourne): $2.5 million to develop a treatment for chronic agitation and aggression linked to dementia. Kinoxis had also recently completed a $6.75 million equity raise.
• TasTest (Tasmania): $2.5 million for a digital self-assessment intended to identify dementia risk decades before symptoms appear.
• Synerva Therapeutics (Victoria): $2.49 million to develop treatments designed to prevent nerve cell death in Parkinson's disease and related dementias.
• Quinthera (Queensland): $2.43 million for an oral treatment targeting brain inflammation associated with Alzheimer's disease and related dementias.
• CodeBreakers (Western Australia): $2.13 million for a gene editing treatment aiming to reverse childhood dementia caused by mitochondrial disease.
• Healthily (Victoria): $1.93 million to build an AI-powered voice platform to detect cognitive decline earlier in older Australians.
• Intracellica Bio (Queensland): $1.61 million for an antibody treatment targeting tau inside cells for Alzheimer's disease and related conditions.

CUREator+ combines grant funding with commercialisation support. According to program head Dr Amanda Vrselja, the complexity of dementia requires multiple scientific and technological approaches. The grants are intended to help researchers and founders take "critical next steps" toward building investable companies and advancing solutions closer to patients. Practical signals for readers tracking the space

• Diversified approaches: The funded projects span small-molecule and biologic therapeutics, gene editing, digital diagnostics and AI-enabled screening. This indicates the program is deliberately funding a range of modalities rather than concentrating on a single pathway.
• Equity-free funding plus commercial support: Recipients receive non-dilutive capital and assistance aimed at commercialization, which can reduce early financial pressure and improve readiness for investment or clinical translation.
• Movement toward trials and commercialisation: One recipient, Kinoxis, combined its grant with an equity raise, showing how grant awards can complement private funding rounds.

The grants move projects forward but do not guarantee clinical success or market entry. Timelines for trials, regulatory milestones, or commercial deployment were not provided in the announcement. Each project will face scientific validation, regulatory review and further funding needs as it progresses.

The CUREator+ round distributes $15.6 million across seven Australian startups tackling dementia and cognitive decline with varied approaches. The funding is equity-free and paired with commercialization support, signaling government interest in accelerating early-stage solutions that could reach patients or investors at later stages.